CAPTRUST Financial Advisors
XENE icon

CAPTRUST Financial Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

CAPTRUST Financial Advisors’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$336K Buy
+5,572
New +$309K ﹤0.01% 2493
2021
Q4 		– Sell
-3,000
Closed -$46K – 4937
2021
Q3 		$46K Buy
+3,000
New +$52.1K ﹤0.01% 2640

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

CAPTRUST Financial Advisors's XENE Position: Q2 2026 in Review

CAPTRUST Financial Advisors opened a new position in Xenon Pharmaceuticals (XENE) in Q2 2026: 5,572 shares worth $336K. The stake represents ﹤0.01% of the portfolio and ranks #2493 among its holdings. This is a return to the name: CAPTRUST Financial Advisors previously reported a position in XENE as recently as Q3 2021.

CAPTRUST Financial Advisors first reported a position in XENE in Q3 2021 and has held it in 2 quarters since. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • CAPTRUST Financial Advisors held 5,572 shares of Xenon Pharmaceuticals worth $336K as of Q2 2026.
  • Xenon Pharmaceuticals was a new CAPTRUST Financial Advisors position in Q2 2026.
  • Xenon Pharmaceuticals made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #2493 holding.
  • CAPTRUST Financial Advisors first reported a position in Xenon Pharmaceuticals in Q3 2021 and has held it in 2 quarters since.
  • 316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.